Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Ignored by the pharmaceutical industry and by public-private partnerships
| The first 150 words of the full text of this article appear below. |
Infectious diseases can be considered
"neglected" when there is a lack of effective, affordable, or
easy to use drug treatments. As most patients with such diseases live
in developing countries and are too poor to pay for drugs, the
pharmaceutical industry has traditionally ignored these diseases. Over
the past decade, however, the public sector, by creating favourable
marketing conditions, has persuaded industry to enter into
public-private partnerships to tackle neglected diseases such as
malaria, HIV, and tuberculosis. Yet some infectious diseases
the
world's "most neglected" diseases
are still being ignored not
just by the pharmaceutical industry but also by public-private partnerships.
Why have these partnerships ignored the most neglected diseases, such as kala-azar, Chagas' disease, and sleeping sickness? This question was explored at a recent meeting in New York, organised by Médecins sans Frontières.1 The answer lies in the social contract that exists between the public and private sectors.
The
Read all Rapid Responses